GameStop Corp. vs Revvity Inc — how do they compare? GameStop Corp. trades at $26.56 (market cap $12.75B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Revvity Inc for 12 Days on average.
| GME | RVTY | |
|---|---|---|
Market Cap | $12.75B | $16.98B |
Volume | 13,026,993 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $157.36 |
52-Week Low | $17.87 | $82.26 |
Typical Hold Time | 62 Days | 12 Days |
Enterprise Value | $12.03B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
GME trades at $26.56, up 8.06% over 24 hours, with a bullish technical signal supported by moving averages. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, while revenue declined to $3.82 billion. Strong insider buying by CEO Ryan Cohen and directors has fueled positive sentiment, though analyst consensus remains cautious with a majority hold rating.
The outlook for GME hinges on execution of its strategic pivot to high-margin collectibles and leveraging its $4.77 billion cash position. Key risks include revenue volatility, competitive pressures, and dependence on insider confidence. Upside potential exists if earnings growth sustains, but investors face uncertainty from inconsistent profitability and high valuation multiples relative to historical performance.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →